Tyrosine Kinase Inhibitors

GoodZ.Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.Nature Medicine.2018

/wp-content/uploads/2024/07/GoodZ.Single-cell-developmental-classification-of-B-cell-precursor-acute-lymphoblastic-leukemia-at-diagnosis-reveals-predictors-of-relapse.Nature-Medicine.2018.pdf

LeonardJ.Aurora A kinase as a target for therapy in TCF3-HLF rearranged ALL Haematologica 2021

/wp-content/uploads/2024/07/LeonardJ.Aurora-A-kinase-as-a-target-for-therapy-in-TCF3-HLF-rearranged-acute-lymphoblastic-leukemia.Haematologica.2021.pdf

OkabeS. Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells.Oncotarget.2018

/wp-content/uploads/2024/07/OkabeS.-Therapeutic-targeting-of-Aurora-A-kinase-in-Philadelphia-chromosome-positive-ABL-tyrosine-kinase-inhibitor-resistant-cells.Oncotarget.2018.pdf

RobertsKG.Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia.NEJM.2014

/wp-content/uploads/2024/07/RobertsKG.Targetable-Kinase-Activating-Lesions-in-Ph-like-Acute-Lymphoblastic-Leukemia.NEJM_.2014.pdf

WarschW. JAK of all trades- JAK2-STAT5 as novel therapeutic targets in BCR-ABL+ chronic myeloid leukemia.Blood.2013

/wp-content/uploads/2024/07/WarschW.-JAK-of-all-trades-JAK2-STAT5-as-novel-therapeutic-targets-in-BCR-ABL11-chronic-myeloid-leukemia.Blood_.2013.pdf

YuanH.Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.Carcinogenesis.2012

/wp-content/uploads/2024/07/YuanH.Overcoming-CML-acquired-resistance-by-specific-inhibition-of-Aurora-A-kinase-in-the-KCL-22-cell-model.Carcinogenesis.2012.pdf

Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse

/wp-content/uploads/2024/07/FoaR.Philadelphia-Chromosome–Positive-Acute-Lymphoblastic-Leukemia.NEJM_.2022.pdf